drugset
Drugs / Allogeneic bone marrow derived mesenchymal stem cells
last change Oct 2023 re-read 3 minutes ago

Allogeneic bone marrow derived mesenchymal stem cells

Cell therapy

Developed for
arterial occlusion · atherosclerosis · limb ischemia · Parkinson disease · peripheral arterial disease
Investigated by
Indiana University · Mya Schiess

Trials 2

today NCT02685098 · Ph 1
20172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02685098 Jan 2017 → Oct 2023 arterial occlusion, atherosclerosis, limb ischemia, peripheral arterial disease Indiana University Completed No outcome recorded
Phase not stated1 trial
— NCT06798064 — Parkinson disease Mya Schiess No longer available No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as Allogeneic bone marrow derived mesenchymal stem cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT02685098 ↗
1

NCT06798064 ↗
Modality Cell therapy “intramuscular injections of allogeneic MSCs” PMID 29395424 ↗ Feb 2018
Route Intramuscular “intramuscular injections of allogeneic MSCs” PMID 29395424 ↗ Feb 2018